On 3 September, icometrix published information about the market approval of a monitoring solution for amyloid-related imaging abnormalities in Alzheimer’s disease. The approval covers several regions, including Europe, Israel, Japan, Switzerland, and the United Kingdom. The need for this monitoring solution comes from the potential side-effects of the novel disease-modifying therapies for Alzheimer's disease, which include specific brain abnormalities known as Amyloid-Related Imaging Abnormalities (ARIA). ARIA can lead to severe neurological complications. Although these abnormalities can be identified through brain MRI scans, detecting and assessing the severity of ARIA is a complex, time-consuming, and challenging process.
The approved solution utilises Artificial Intelligence-based algorithms to detect and measure ARIA on brain MRI scans. It provides assessments for both ARIA subtypes: ARIA-E (edema) and ARIA-H (hemorrhage). Validation studies have demonstrated that the solution offers significant benefits for radiologists. It improves reading performance, reduces the time required to assess ARIA, enhances agreement between readers on ARIA severity, and increases diagnostic accuracy. These improvements are beneficial for both general and specialised radiologists, according to the company. Further information: https://icometrix.com/resources/icometrix-is-proud-to-announce-the-market-approval-of-icobrain-aria